However an accompanying Comment cautions the findings are only applicable to patients having periods of maximum virological suppression, and thus have limited application in low income countries.
Dr Amanda Mocroft, Royal Free Centre for HIV Medicine, Royal Free and University College London Medical Schools, and colleagues did a study of 1835 antiretroviral-naive patients from EuroSIDA, a pan-European observational cohort study. These patients, with a mean CD4 cell count of 204 cells per microlitre of blood, then started cART. They were selected because they all responded well to cART and their HIV viral loads were suppressed to below 50 copies per ml for extended periods of time.
The researchers found that the greatest average yearly increase in CD4 count of 100 cells per microlitre was seen in the year immediately following the start of cART. Significant, but lower, yearly increases of around 50 cells per microlitre were seen even five years after beginning cART in some cases, in which patients whose current CD4 count was below 500 cells per microlitre. Patients starting cART with low CD4 cell counts (of less than 200 cells per microlitre) had substantial rises in CD4 counts even after five years. The only groups without substantial increases in CD4 count were those where cART had been taken for more than five years with a current CD4 count of more than 500 cells per microlitre.
The authors conclude: “Normalisation of CD4 counts in HIV-infected patients for all infected individuals might be achievable if viral suppression with cART can be maintained for a sufficiently long period of time.
“We have shown that most patients with HIV who can maintain viral load at less than 50 copies per ml continue to have significant rises in CD4 counts, even after protracted exposure to combination therapy.
“Patients who started cART with a CD4 cell count of more than 350 cells per microlitre had CD4 cells counts approaching the level seen in HIV-negative individuals after more than three years of cART and had no further significant rises in CD4 counts.”
In the accompanying Comment, Dr Gary Maartens and Dr Andrew Boulle, University of Cape Town, South Africa, point out that CD4 cell count when patients start cART is the most important factor is predicting survival – not count increases after cART has begun.
They say: “Mocroft and colleagues’ findings that CD4 counts continue to increase on cART until normal values are reached, even with low CD4 counts at baseline, is only generalisable to patients on cART during periods of maximum virological suppression.”
They conclude: “Nevertheless, the researchers have shown that at least for patients with ideal responses to cART, normalisation of CD4 counts is likely to be achievable across a range of baseline counts.”
Tony Kirby | alfa
Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Power and Electrical Engineering
14.12.2018 | Physics and Astronomy
14.12.2018 | Physics and Astronomy